- Home
- DYAI vs ARMP Comparison
DYAI vs ARMP Comparison
Compare DYAI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- ARMP
- Stock Information
- Founded
- DYAI 1979
- ARMP N/A
- Country
- DYAI United States
- ARMP United States
- Employees
- DYAI N/A
- ARMP N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DYAI Health Care
- ARMP Health Care
- Exchange
- DYAI Nasdaq
- ARMP Nasdaq
- Market Cap
- DYAI 35.5M
- ARMP 52.1M
- IPO Year
- DYAI 2004
- ARMP N/A
- Fundamental
- Price
- DYAI $1.07
- ARMP $1.29
- Analyst Decision
- DYAI Strong Buy
- ARMP Strong Buy
- Analyst Count
- DYAI 1
- ARMP 1
- Target Price
- DYAI $6.00
- ARMP $7.00
- AVG Volume (30 Days)
- DYAI 35.9K
- ARMP 13.6K
- Earning Date
- DYAI 05-14-2025
- ARMP 05-20-2025
- Dividend Yield
- DYAI N/A
- ARMP N/A
- EPS Growth
- DYAI N/A
- ARMP N/A
- EPS
- DYAI N/A
- ARMP N/A
- Revenue
- DYAI $3,495,389.00
- ARMP $5,174,000.00
- Revenue This Year
- DYAI $117.40
- ARMP $8.43
- Revenue Next Year
- DYAI N/A
- ARMP N/A
- P/E Ratio
- DYAI N/A
- ARMP N/A
- Revenue Growth
- DYAI 20.58
- ARMP 14.24
- 52 Week Low
- DYAI $0.93
- ARMP $0.90
- 52 Week High
- DYAI $2.67
- ARMP $3.45
- Technical
- Relative Strength Index (RSI)
- DYAI 28.15
- ARMP 43.79
- Support Level
- DYAI $1.05
- ARMP $1.29
- Resistance Level
- DYAI $1.21
- ARMP $1.70
- Average True Range (ATR)
- DYAI 0.07
- ARMP 0.17
- MACD
- DYAI -0.01
- ARMP 0.01
- Stochastic Oscillator
- DYAI 8.33
- ARMP 8.89
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.